Jeffrey Blum, MD
American Board of Internal Medicine
American Board of Internal Medicine - Cardiovascular Disease
Fellowship, Cardiology - Manhattan Veterans Administration, New York University Medical Center - New York, NY (1990-2003)
Residency, Internal Medicine - Beth Israel Medical Center - New York, NY (1986-1988)
Internship, Internal Medicine - Beth Israel Medical Center - New York, NY (1985-1986)
Eastern Virginia Medical School - M.D. - Norfolk, VA (1985)
University of Virginia - B.A. - Charlottesville, VA (1980)
American College of Cardiology
American Heart Association
Florida Medical Association
Dade County Medical Association
LET Study: A prospective, open label randomized comparison of two treatment regiment: Cozaar and Hyzaar versus usual care inpatients previously treated for mild to moderate hypertension who need a change in drug therapy.
CARE Study: Cholesterol and recurrent events: A secondary prevention trial of lowering blood cholesterol after myocardial infarction.
A randomized, multicenter, double-blind, placebo-controlled forced dose titration study comparing PPR Verapamil 240 mg/480 mg to Norvasc 5 mg/10 mg with and without Atenolol 50 mg in patients with chronic stable angina.
LIFE Study: A triple-blind parallel study to investigate the effect of Losartan versus Atenolol on the reduction of morbidity and mortality in hypertensive patients with left ventricular hypertrophy.
Collaborative Study Group: The effect of Irbesartan on morbidity and mortality in hypertensive patients with type II diabetes and diabetic nephropathy.
ACCESS Study: A 54-week open-label assessment of the safety and efficacy profile of Atorvastatin as compared to Fluvastatin, Lovastatin, Simvastatin and Pravastatin when used to optimally control primary hypercholesterolemia (Type II A) and mixed dyslipidema (Type II B)
Valsartan Study: Multicenter, randomized, double-blind, placebo-controlled, parallel trial to assess the effect of Valsartan on exercise capacity, quality of life and signs and symptoms in patients with stable, chronic congestive heart failure (NYHA Class II-IV).
EXCITE Trial: Clinical protocol for efficacy and safety of Xemilofiban Hydrochloride (SC-54684A), administration to patients undergoing coronary angioplasty or stent placement.
The Wizard Trial: A randomized, double-blind, placebo controlled trial of the effect of weekly Azithromycin on the incidence of coronary artery disease in subjects with evidence of exposure of C. pneumoniae.
A multicenter, randomized, double-blind, placebo-controlled, parallel 9-week study of Omapatrilat (BMS-186716) in the treatment of mild to moderate hypertension.
TNT: The effect of LDL Cholesterol lowering beyond currently recommended minimum targets on coronary heart disease (CHD) recurrence in patients with pre-existing CHD.
NIASPAN: An open-label, community based clinical practice study of Niaspan in patients with hyperlipidemia.
SYMPHONY: A Phase III, multicenter, international, randomized, double-blind, aspirin controlled study to evaluate the efficacy and safety of sibrafiban (RO 48-3657), an oral platelet glycoprotein IIb/IIa antagonist, as therapy for the prevention of secondary vascular events in patients after an Acute Coronary Syndrome.
LESCOL: A sixteen-week, double-blind and observer blind-to-lipid values, randomized, paralles group, multicenter, active-controlled study to assess the efficacy and safety of Fluvastatin 80 mg and pRavastatin 40 mg administered once daily every evening.